Less Ads, More Data, More Tools Register for FREE

Pin to quick picksChemring Regulatory News (CHG)

Share Price Information for Chemring (CHG)

Share Price is delayed by 15 minutes
Get Live Data
499.40    -0.60 (-0.12%)
Bid:
500.00
Ask:
501.00
Spread: 1.00 (0.20%)
Market Cap: £1.35b
CHG Live PriceLast checked at - London Stock Exchange

Intraday Chemring Share Chart

Contract Award

2 Apr 2025 07:00

RNS Number : 2155D
Chemring Group PLC
02 April 2025
 

FOR IMMEDIATE RELEASE 2 APRIL 2025

 

CHEMRING GROUP PLC ("Chemring", the "Group" or the "Company")

 

ROKE SECURES LONG-TERM UK MISSILE DEFENCE CENTRE CONTRACT

 

Chemring is pleased to announce that Roke has won a strategically important UK Ministry of Defence multi-year missile defence contract.

 

Known as Science & Technology Oriented Research & development in Missile defence ("STORM"), this framework contract encompasses a broad spectrum of missile defence activities and capabilities. Partnering with the UK Missile Defence Centre ("UK MDC") Roke will lead a UK sovereign industry collaborative effort to provide security to the UK, and its allies, by countering current and future threats, including ballistic and hypersonic missiles.

 

Valued at £251m over six years, and commencing immediately, the STORM framework will see Roke enhance its role as a trusted partner to the UK MDC at the heart of the UK missile defence ecosystem at what is a pivotal moment for national defence and security. As the overall Prime Contractor Roke will self-deliver elements of the contract and will also manage industry partners as they deliver the significant majority of contract value.

 

Roke's STORM work will inform critical UK defence decision-making and will play a key role in developing next-generation missile defence capabilities.

 

Michael Ord, Chief Executive of Chemring, commented:

 

"We are delighted that Roke has been trusted to deliver STORM for the UK MDC. In today's complex and changing security environment effective missile defence is crucial to protecting the UK's interests. This contract recognises Roke's heritage in helping customers solve complex problems, and places Roke at the heart of the UK's missile defence research and development activities."

 

ENDS

 

For further information:

Rupert Pittman Group Director of Corporate Affairs, 01794 463401

Chemring Group PLC

 

James McFarlane MHP Group 07584 142665

Ollie Hoare 07817 458804

 

 

Cautionary statement

 

This announcement may contain forward-looking statements that are based on current expectations or beliefs, as well as assumptions about future events. These forward-looking statements can be identified by the fact that they do not relate only to historical or current facts. Forward-looking statements often use words such as anticipate, target, expect, estimate, intend, plan, goal, believe, will, may, should, would, could, is confident, or other words of similar meaning. Undue reliance should not be placed on any such statements because they speak only as at the date of this document and, by their very nature, they are subject to known and unknown risks and uncertainties and can be affected by other factors that could cause actual results, and Chemring's plans and objectives, to differ materially from those expressed or implied in the forward-looking statements. There are a number of factors which could cause actual results to differ materially from those expressed or implied in forward-looking statements. Among the factors that could cause actual results to differ materially from those described in the forward-looking statements are: increased competition, the loss of or damage to one or more key customer relationships, changes to customer ordering patterns, delays in obtaining customer approvals for engineering or price level changes, the failure of one or more key suppliers, the outcome of business or industry restructuring, the outcome of any litigation, changes in economic conditions, currency fluctuations, changes in interest and tax rates, changes in raw material or energy market prices, changes in laws, regulations or regulatory policies, developments in legal or public policy doctrines, technological developments, the failure to retain key management, or the key timing and success of future acquisition opportunities or major investment projects. Chemring undertakes no obligation to revise or update any forward-looking statement contained within this announcement, regardless of whether those statements are affected as a result of new information, future events or otherwise, save as required by law and regulations.

 

Notes to editors

 

· Chemring is a FTSE250 global business that specialises in the manufacture of high technology products and the provision of services to the aerospace, defence and security markets

· Employing approximately 2,700 people worldwide, and with production facilities in four countries, Chemring meets the needs of customers in more than fifty countries

· Chemring is organised under two strategic product segments: Sensors & Information and Countermeasures & Energetics

· Chemring has a diverse portfolio of products that deliver high reliability solutions to protect people, platforms, missions and information against constantly changing threats

· Operating in niche markets and with strong investment in research and development ("R&D"), Chemring has the agility to rapidly react to urgent customer needs

 

www.chemring.com

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
CNTPKDBQPBKDFQK
Date   Source Headline
3rd Apr 20253:20 pmRNSHolding(s) in Company - Replacement
3rd Apr 20257:00 amRNSTransaction in Own Shares
2nd Apr 20257:00 amRNSTransaction in Own Shares
2nd Apr 20257:00 amRNSContract Award
1st Apr 20257:00 amRNSTransaction in Own Shares
1st Apr 20257:00 amRNSTotal Voting Rights
31st Mar 20252:57 pmRNSHolding(s) in Company
31st Mar 20257:00 amRNSTransaction in Own Shares
28th Mar 20257:00 amRNSTransaction in Own Shares
27th Mar 20257:00 amRNSTransaction in Own Shares
26th Mar 20257:00 amRNSTransaction in Own Shares
25th Mar 20257:00 amRNSTransaction in Own Shares
24th Mar 20257:00 amRNSTransaction in Own Shares
21st Mar 20257:00 amRNSTransaction in Own Shares
20th Mar 20257:00 amRNSTransaction in Own Shares
14th Mar 20257:00 amRNSTransaction in Own Shares
13th Mar 20257:00 amRNSTransaction in Own Shares
5th Mar 20251:46 pmRNSDirector/PDMR Shareholding
4th Mar 20257:00 amRNSTransaction in Own Shares
3rd Mar 20257:01 amRNSTotal Voting Rights
3rd Mar 20257:00 amRNSTransaction in Own Shares
28th Feb 20257:00 amRNSTransaction in Own Shares
27th Feb 20254:12 pmRNSHolding(s) in Company
27th Feb 20252:43 pmRNSDirector/PDMR Shareholdings
27th Feb 20258:00 amRNSHolding(s) in Company
27th Feb 20257:00 amRNSTransaction in Own Shares
26th Feb 20251:29 pmRNSResult of AGM
26th Feb 20257:00 amRNSAGM Update
25th Feb 20253:50 pmRNSHolding(s) in Company
21st Feb 20252:54 pmRNSHolding(s) in Company
3rd Feb 20257:00 amRNSTotal Voting Rights
27th Jan 20253:59 pmRNSNotice of AGM
14th Jan 20257:00 amRNSRoke Contract Award
2nd Jan 202511:01 amRNSTotal Voting Rights
19th Dec 20247:00 amRNSAdditional Listing
18th Dec 20241:30 pmRNSDirector/PDMR Shareholding
18th Dec 20241:30 pmRNSDirector/PDMR Shareholding
18th Dec 20241:30 pmRNSDirector/PDMR Shareholding
18th Dec 20241:30 pmRNSDirector/PDMR Shareholding
18th Dec 20241:30 pmRNSDirector/PDMR Shareholding
18th Dec 202410:30 amRNSDirector/PDMR Shareholding
18th Dec 202410:30 amRNSDirector/PDMR Shareholding
18th Dec 202410:30 amRNSDirector/PDMR Shareholding
18th Dec 202410:30 amRNSDirector/PDMR Shareholding
18th Dec 202410:30 amRNSDirector/PDMR Shareholding
18th Dec 202410:30 amRNSDirector/PDMR Shareholding
18th Dec 20247:00 amRNSBlock listing Interim Review
17th Dec 202412:49 pmRNSDirector/PDMR Shareholding
17th Dec 20247:00 amRNSResults for the year ended 31 October 2024
5th Dec 20247:00 amRNSDirectorate Change

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.